Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DCK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Wild-Type Enzyme | DCK Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/μg. Sequence Verified, Theoretical MW confirmed by Mass Spec. Intracellular target formulation. |
View DCK Products |
| Resistance Mutants | DCK L264V / R104X / E64stop Mutant Proteins Clinically relevant resistance variants. High Purity (>95%), Activity-compatible folding verified. |
View DCK Products |
| Gene Delivery | DCK Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View DCK Products |
| Benchmark Ab | Anti-DCK Recombinant Antibody Sequence-defined, rational epitope design for Western Blot, IP, and ELISA. |
View DCK Products |
| Validator | DCK siRNA Set (3 unique targets) For knockdown verification and resistance modeling. |
View DCK Products |
| Related Target: CMPK1 | Downstream kinase in the nucleoside phosphorylation salvage pathway. | View CMPK1 Products |
| Related Target: RRM1 | Ribonucleotide reductase subunit, critical for de novo dNTP synthesis and synergistic targeting. | View RRM1 Products |
| Related Target: TK1 | Thymidine Kinase 1; parallel deoxyribonucleoside kinase pathway for selectivity screening. | View TK1 Products |
| Related Target: SLC29A1 (ENT1) | Equilibrative Nucleoside Transporter 1; upstream transporter mediating nucleoside analog uptake. | View SLC29A1 Products |
| Related Target: SAMHD1 | Counter-regulates intracellular dNTP pools; emerging bypass mechanism for nucleoside analog efficacy. | View SAMHD1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Activity Validation | Highly purified recombinant DCK expressed in optimized systems (HEK293) to preserve native folding and enzymatic capacity. High concentration (>2 mg/mL) stable protein. |
| Resistance Mutation Screening (L264V, R104X, E64stop) | Clinically-validated mutant panel available; Sequence Verified; >95% purity; Endotoxin controlled for cellular rescue assays. |
| Selectivity vs. TK1 / TK2 Off-target | Human/Mouse DCK + TK1 Ortholog Panel; Strict mass spec identity verification. |
| Modeling Chemo-Resistance | Comprehensive panel of clinically relevant mutant proteins strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies and validated siRNA included for rigorous assay standardization and specificity checks. |
| False Positives in Screening | Validated siRNA included for specificity checks and cellular dependency assays. |
Live DCK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Deoxycytidine kinase (DCK) is the rate-limiting enzyme in the deoxyribonucleoside salvage pathway and is essential for the intracellular activation of numerous nucleoside analog prodrugs widely used in oncology (e.g., gemcitabine, cytarabine) and antiviral therapies. The race for DCK-related therapeutics is intensifying, with major players focusing on overcoming tumor resistance caused by DCK downregulation or mutation (e.g., L264V, R104X, E64stop). As first-generation nucleoside analogs continue to be standard-of-care, the next wave of R&D is targeting direct DCK modulators, novel prodrugs designed to bypass DCK deficiency, and PET imaging probes (like 18F-FAC) to stratify patients based on tumor DCK activity. Simultaneously, DCK is emerging as a validated suicide gene therapy target, where viral delivery of DCK enables selective activation of non-toxic prodrugs (e.g., BVDU) in tumor cells. This dual modality—small molecule resistance profiling and gene therapy enzymology—drives demand for high-fidelity DCK reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic/Biotech Consortiums | T-cell Malignancies, Autoimmune | Kinase Activity Assays (Need active recombinant DCK) |
| Nucleoside Analogs (Resistance Profiling) | Eli Lilly, Novartis, Academic Consortia | AML, Pancreatic Cancer, NSCLC | Mutant vs WT Enzyme Kinetics (Need L264V/R104X Mutant Proteins) |
| Gene Therapy / mRNA | Emerging Biotechs, University spin-offs | Chemo-refractory Tumors, Solid Tumors (GBM, Prostate) | Stable Cell Line Construction (Need DCK Lentivirus) |
| Suicide Gene Therapy | University spin-offs, Gene therapy Biotechs | Solid Tumors (GBM, Prostate) | Expression Validation (Need sequence-verified ORF/Lentivirus) |
| PET Imaging Probes | Diagnostics Companies | Companion Diagnostics (Oncology) | Binding Affinity Assays (Need structurally intact protein) |
| Combination Therapy (DCK + Transporter) | Oncology focused Pharma | Refractory Leukemia | Pathway Panel Screening (Need SLC29A1 + DCK Co-expression) |